Table 1 Baseline characteristics of the patients by treatment group.
Initiating abacavir | Initiating tenofovir | P a | |
|---|---|---|---|
N | 28 | 22 | - |
Characteristics at study entry | |||
Male, (%) | 71 | 91 | 0.088 |
Age (yrs), median (IQR) | 35 (32-43) | 40 (35-46) | 0.042 |
Time on ART (yrs)b, median (IQR) | 2.5 (0.75-5.0) | 1 (0.55-3.25) | 0.463 |
ART received during the study period | |||
PI based (%) | 32 | 27 | 0.477 |
NNRTI based (%) | 68 | 73 | 0.477 |
CD4 cell count (cells/mm3), median (IQR) | 260 (152-357) | 200 (150-252) | 0.072 |
Lipodystrophy (%) | 3.5 | 13.6 | 0.308 |
Prior cardiovascular disease (%) | 0 | 0 | - |
Hypertension (%) | 7.1 | 4.5 | 0.591 |
Systolic blood pressure (mmHg), median (IQR) | 124 (112-130) | 119 (111-140) | 0.747 |
Diastolic blood pressure (mmHg), median (IQR) | 74 (68-85) | 72 (63-83.5) | 0.518 |
Diabetes (%) | 0 | 0 | - |
Current smokers (%) | 75 | 81 | 0.411 |
Lipid-lowering drugs (%) | 3.6% | 4.5% | 0.691 |
Total cholesterol (mg/dL), median (IQR) | 173 (134-189) | 165 (126-201) | 0.822 |
LDL-cholesterol (mg/dL), median (IQR) | 99 (84-122) | 94 (72-126) | 0.747 |
HDL-cholesterol (mg/dL), median (IQR) | 38 (33-46) | 42 (30-45) | 0.792 |
Triglycerides (mg/dL), median (IQR) | 115 (80-159) | 112 (89-179) | 0.591 |
Framingham risk score, median (IQR) | 6.0 (1.5-10) | 7.5 (3.3-13.3) | 0.417 |
Framingham risk at 10 yrsc, median (IQR) | 2 (1-6) | 3.5 (1-13) | 0.512 |
Hepatitis C-virus coinfection (%) | 53 | 45 | 0.577 |
eGFRd (ml/min*1.73m2), median (IQR) | 87.1 (78.3-107.1) | 85.8 (67.0-93.2) | 0.120 |
hsCRP levels (mg/L), median (IQR) | 1.5 (0.5-3.2) | 1.7 (0.6-3.6) | 0.845 |
IL-6 levels (ρg/mL), median (IQR) | 0.8 (0.3-2.7) | 2.7 (0.8-5.6) | 0.079 |
sVCAM-1 (ηg/mL), median (IQR) | 818 (524-1088) | 889 (778-1354) | 0.315 |
sICAM-1 (ηg/mL), median (IQR) | 499 (370-955) | 485 (444,-) | 0.840 |
PAI-1 (ηg/mL), median (IQR) | 2.6 (1.5-7.1) | 2.8 (1.4-4.3) | 0.710 |